Overview

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

Status:
COMPLETED
Trial end date:
2024-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential difference between pharmacokinetics (PK), safety, tolerability and device performance between the AZD8630 test formulation and the AZD8630 reference formulation.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca